AGL 38.15 Decreased By ▼ -1.43 (-3.61%)
AIRLINK 125.07 Decreased By ▼ -6.15 (-4.69%)
BOP 6.85 Increased By ▲ 0.04 (0.59%)
CNERGY 4.45 Decreased By ▼ -0.26 (-5.52%)
DCL 7.91 Decreased By ▼ -0.53 (-6.28%)
DFML 37.34 Decreased By ▼ -4.13 (-9.96%)
DGKC 77.77 Decreased By ▼ -4.32 (-5.26%)
FCCL 30.58 Decreased By ▼ -2.52 (-7.61%)
FFBL 68.86 Decreased By ▼ -4.01 (-5.5%)
FFL 11.86 Decreased By ▼ -0.40 (-3.26%)
HUBC 104.50 Decreased By ▼ -6.24 (-5.63%)
HUMNL 13.49 Decreased By ▼ -1.02 (-7.03%)
KEL 4.65 Decreased By ▼ -0.54 (-10.4%)
KOSM 7.17 Decreased By ▼ -0.44 (-5.78%)
MLCF 36.44 Decreased By ▼ -2.46 (-6.32%)
NBP 65.92 Increased By ▲ 1.91 (2.98%)
OGDC 179.53 Decreased By ▼ -13.29 (-6.89%)
PAEL 24.43 Decreased By ▼ -1.25 (-4.87%)
PIBTL 7.15 Decreased By ▼ -0.19 (-2.59%)
PPL 143.70 Decreased By ▼ -10.37 (-6.73%)
PRL 24.32 Decreased By ▼ -1.51 (-5.85%)
PTC 16.40 Decreased By ▼ -1.41 (-7.92%)
SEARL 78.57 Decreased By ▼ -3.73 (-4.53%)
TELE 7.22 Decreased By ▼ -0.54 (-6.96%)
TOMCL 31.97 Decreased By ▼ -1.49 (-4.45%)
TPLP 8.13 Decreased By ▼ -0.36 (-4.24%)
TREET 16.13 Decreased By ▼ -0.49 (-2.95%)
TRG 54.66 Decreased By ▼ -2.74 (-4.77%)
UNITY 27.50 Decreased By ▼ -0.01 (-0.04%)
WTL 1.29 Decreased By ▼ -0.08 (-5.84%)
BR100 10,089 Decreased By -415.2 (-3.95%)
BR30 29,509 Decreased By -1717.6 (-5.5%)
KSE100 94,574 Decreased By -3505.6 (-3.57%)
KSE30 29,445 Decreased By -1113.9 (-3.65%)

Denmark's Novo Nordisk, the world's leading insulin manufacturer, announced Monday an offer to buy the Belgian biotech firm Ablynx for 2.6 billion euros ($3.1 billion). Novo Nordisk said it made an initial offer in December and then raised it, but that it had been rejected by Ablynx's managment. "Novo Nordisk encourages Ablynx's Board of Directors to engage in a negotiated transaction for the benefit of all stakeholders," the Danish firm said in a statement.
The initial offer of 26.75 euros in cash was raised to 28 euros per share in cash plus up to another 2.50 euros per share depending on performance. Ablynx said in a statement that its board "concluded that the proposal fundamentally undervalues Ablynx and its strong prospects for continued growth."
Ablynx specialises in the development of nanobodies: small fragments of antibodies that like larger antibodies can bind onto the antigens that cause an immune system response. Novo Nordisk said its strong global haematology franchise would make it able to better develop one of those nanobodies, caplacizumab, which aims to treat a certain type of blood clots.
It called its buyout offer a "compelling opportunity and provides the clearest path to realizing full potential of Ablynx's portfolio in the best interests of all stakeholders, including patients and physicians." The offer is the largest ever by Novo Nordisk for another pharmaceutical firm, according to Bloomberg News.
The firm accounts for nearly half of the global market for insulin, but is also present in other sectors such as horomone treatments and drugs to control haemophilia. Its shares were down a quarter of a percent in trading on the Copenhagen stock exchange at 339.10 kronor. Shares in Ablynx were suspended on Monday morning in Brussels at the request of the market regulator.

Copyright Agence France-Presse, 2018

Comments

Comments are closed.